In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.

@article{Gmez2003InVT,
  title={In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.},
  author={Susana Guzm{\'a}n G{\'o}mez and Juan Antonio Bueren and Glynn Thomas Faircloth and Jos{\'e} Mar{\'i}a Jimeno and Beatriz Albella},
  journal={Experimental hematology},
  year={2003},
  volume={31 11},
  pages={
          1104-11
        }
}
OBJECTIVE In addition to neutropenias and/or thrombocytopenias as a short-term effect, antineoplastics also can produce long-term effects as a consequence of damage to the hematopoietic stem cells. The aim of the present study was to evaluate the toxicity of three marine-derived antineoplastics on murine hematopoietic stem cells. These antitumoral compounds currently are being evaluated in patients in phase II (aplidin and kahalalide F) and phase II/III (trabectedin) clinical trials… Expand
evelopment of an in vitro model for the simultaneous study of the efficacy and ematotoxicity of antileukemic compounds
Hematopoietic system displays a wide spectrum of cell populations hierarchically organized in the bone marrow. Homeostasis in this system requires equilibrium between the self-renewal of the stemExpand
Development of an in vitro model for the simultaneous study of the efficacy and hematotoxicity of antileukemic compounds.
TLDR
The results show that this in vitro model is a valuable tool for studying the effect of antitumoral compounds in both tumoral and normal hematopoietic cells under the same toxic microenvironment and could safe time and facilitate the reduction of the number of animals used in preclinical development of pharmaceuticals. Expand
Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro
TLDR
The data show that bendamustine is characterized by lower in vitro toxicity to hematopoietic progenitors and stem cells than fludarabine and might thus be preferable in regimens prior to stem cells apheresis. Expand
Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
TLDR
Data indicate that Aplidin is well tolerated in vivo and its antitumour and antiangiogenic effects support the use of the drug in multiple myeloma. Expand
Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab
TLDR
The in vitro synergy and the in vivo additive antitumor effects without an increase in host toxicity with two relatively non-marrow suppressive agents encourages further development of this combination for treatment of aggressive B-cell lymphomas. Expand
Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity
TLDR
Whole genome gene-expression profiling (GEP) revealed that fatty acid metabolism, sterol biosynthesis and energy metabolism, including the tricarboxylic acid cycle and ATP synthesis are affected by Aplidin treatment, and mutant MOLT-4, human leukemia cells lacking functional mitochondria, were found to be resistant to APLidin. Expand
CXCR4‐independent rescue of the myeloproliferative defect of the gata1low myelofibrosis mouse model by Aplidin®
TLDR
Results indicate that Aplidin® effectively alters the natural history of myelofibrosis in Gata1low mice and suggest this drug as candidate for clinical evaluation in PMF. Expand
ET-743: a novel agent with activity in soft-tissue sarcomas
TLDR
ET-743 is a novel active drug for sarcoma which yields prolonged disease-free survival in subsets of patients and the results of the follow-up Phase III trial should be available at the American Society of Clinical Oncology meeting of 2006. Expand
ET-743: a novel agent with activity in soft tissue sarcomas.
TLDR
In several phase II clinical studies in patients with advanced sarcoma failing conventional doxorubicin- and ifosfamide-based chemotherapy, ET-743 delivered by continuous intravenous 24-hour infusion at a dose of 1,500 microg/m2 every 21 days yielded 8% overall response and 30%-40% stabilization rates for a clinical benefit rate close to 40%. Expand
Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
TLDR
The mechanisms of action, the complex metabolism, the main toxicities, the preclinical and clinical evidences of its antineoplastic effects in different types of cancer and, finally, the future perspectives of this promising drug are summarized. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 34 REFERENCES
In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.
TLDR
Aiming to further improve the predictive value of in vitro IC values corresponding to the different haematopoietic progenitors, additional refinement parameters derived from pharmacokinetic and animal studies are proposed. Expand
Latent hematopoietic stem cell toxicity associated with protracted drug administration.
TLDR
The data show that protracted treatment with gemcitabine, but not acetyldinaline, of mice caused severe permanent damage to the stem cell components, which means that 28-day therapy with gem citabine or gemcitABine appears to be well tolerated at the level of peripheral blood and bone marrow progenitors, but produces permanent stem cell damage when used in long-term administration regimens that should be explored clinically with stem cell support available. Expand
Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay
TLDR
Long-lasting proliferative defects in the primitive hematopoietic stem-cell (PHSC) population can result from the use of chemotherapeutic agents, which may have clinical implications in individuals receiving repeated or prolonged administration of these agents or in instances of marrow transplantation. Expand
Comparison of the sensitivities of human, canine, and murine hematopoietic precursor cells to adriamycin and N-trifluoroacetyladriamycin-14-valerate.
  • J. Marsh
  • Biology, Medicine
  • Cancer research
  • 1979
TLDR
Human stem cells were relatively more sensitive to AD32 than were mouse stem cells, and Granulocytopenia may be an important limiting toxicity in the clinical use of AD32. Expand
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
  • D. Ryan, J. Supko, +7 authors J. Clark
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2001
Ecteinascidin 743 (ET-743) is a cytotoxic tetrahydroisoquinoline alkaloid that covalently binds to DNA in the minor groove. The in vitro chemosensitivity of cancer cells to ET-743 is markedlyExpand
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
TLDR
The RD for a 24-hour continuous intravenous infusion of ET-743 is 1,500 microg/m(2), with the most prevalent DLTs being hematologic, and Pharmacokinetic studies were performed on all patients for at least the first cycle, giving a linear pharmacokinetic profile. Expand
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
TLDR
The acceptable toxicity profile of ET-743 on the divided-dose schedule evaluated in this trial, as well as the generally superior antitumor activity associated with divided- dose schedules in preclinical studies, provides a rationale for further evaluation ofET- 743 on this administration schedule. Expand
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine
TLDR
The cell cycle phase perturbations and the rapid induction of apoptosis in Molt-4 cells appear to be due to a mechanism different from that of known anticancer drugs. Expand
Relevance of myeloablative conditioning in the engraftment of limiting numbers of normal and genetically marked lympho-hematopoietic stem cells.
TLDR
The administration of high doses of split-dose irradiation to mice transplanted with small grafts of normal BM not only minimized the endogenous reconstitution of recipients but also increased, with respect to single irradiation protocols, the survival rate of the animals in the long-term. Expand
High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
TLDR
Ecteinascidin-743 is a very effective agent inChemo-sensitive and marginal chemo-resistant xenografts, but inactive in cheme-resistant tumour xenografteds. Expand
...
1
2
3
4
...